Ontex Overview
Ontex is a mid-sized European manufacturer of disposable personal hygiene products — adult incontinence, baby diapers and pants, and feminine care — sold predominantly under retailers' own labels and to healthcare channels, with a small portfolio of owned healthcare brands. After a four-year portfolio clean-up that sold all Emerging Markets operations (Mexico, Algeria, Pakistan, Brazil, Turkey), the group now generates ~€1.74bn of revenue from Europe and North America. Adult care has become the largest category (~47% of revenue in FY2025) and the designated growth pillar, while baby care — historically the core — is under structural pressure from falling birth rates, A-brand promotional intensity and retailer-brand share loss. The company is in a second-phase turnaround under CEO Laurent Nielly (since January 2026): a €240m "Focus to Value" savings programme, a profitability-first reset in North America, €144m of impairments, and a new CFO. With leverage at ~3.2x, bonds trading near 87% of par and Russia (≈5% of revenue) placed under Kremlin interim administration in October 2026, Ontex is a stressed small-cap equity whose value hinges on execution.
Company's own description
Ontex describes itself (H1 2026 press release, Jul 2026) as a leading international developer and producer of baby care, feminine care and adult care products, serving both retailers and healthcare, primarily in Europe and North America. Its corporate website adds that it partners with retailers and healthcare providers and is trusted by over 35 million people (ontex.com, 2026).
What the company does
Ontex designs, develops and manufactures absorbent hygiene products (AHPs) on high-speed converting lines that combine fluff pulp, superabsorbent polymer (SAP), nonwovens, films, elastics and adhesives. Its three categories are:
Adult care (incontinence): light incontinence pads, medium/heavy incontinence briefs (all-in-ones), pull-up pants, underpads and related products, sold to (a) healthcare channels — hospitals, nursing homes, home-care distributors and reimbursed tender systems in several European countries — and (b) retail (retailer-brand pads and pants). Adult care revenue was €814.1m in FY2025 (+1.6% LFL).
Baby care: baby diapers (tape), baby pants (pull-ups) and, historically, wipes; sold mainly as retailer brands across Europe and North America and as contract manufacturing for third parties in North America. Revenue €696.6m in FY2025 (−11% LFL).
Feminine care: sanitary towels, pantyliners and tampons, predominantly retailer brands in Europe plus contract manufacturing. Revenue €228.2m in FY2025 (−3.3% LFL).
(Source: Ontex FY2025 results press release, 12 Feb 2026.)
Business model and revenue model
| Dimension | Characterization |
|---|---|
| Revenue model | ~100% product sales. No material service, subscription or licensing revenue disclosed |
| Channel model | (1) Retailer brands (private label) — Ontex manufactures to retailer specification, often under multi-year supply contracts won through tenders; (2) Healthcare — owned brands and tender supply into institutional and reimbursed channels; (3) Contract manufacturing — production for other brand owners, around one-third of North American revenue (FY2025 results presentation) |
| Value chain position | Mid-stream converter: buys commodity/semi-specialty inputs (pulp, SAP, polypropylene nonwovens, films) and converts them into finished goods; it does not own retail distribution (except healthcare logistics in some markets) |
| Pricing dynamic | Contracted or index-linked pricing with retailers; pass-through lags input-cost moves by one or more quarters (illustrated in H1 2026, when oil-derivative and freight costs rose faster than pricing actions) |
| Cost structure | Raw materials are the largest cost block; fixed-cost absorption is significant, so volume swings drive outsized margin moves (FY2025: −5% volume drove a 2pp adj. EBITDA margin contraction) |
Customers and end-markets
Customer types: large grocery and discount retailers and drugstore chains in Europe (named customers not disclosed), large US retailers (not named), healthcare providers and distributors, public tender bodies, and third-party brand owners (contract manufacturing).
End-markets: Western, Central and Eastern Europe (including Russia via a local subsidiary), North America (US, supplied from Stokesdale, North Carolina and Tijuana, Mexico — the latter USMCA-compliant), and selected overseas markets (including Australia via an Eastern Creek plant; "contract exits in other overseas markets" were cited in H1 2026).
Independent characterization
Ontex is a scale private-label converter in a category dominated by global A-brands (P&G, Kimberly-Clark, Essity). Its economic moat is limited to (i) manufacturing cost and quality at scale, (ii) long-standing retailer relationships, (iii) healthcare-channel know-how in adult incontinence, and (iv) innovation speed for retailer brands (e.g., baby pants, skin-health adult products). The business is structurally exposed to: raw-material price volatility; A-brand promotional cycles that compress the price gap with private label; demographic decline in baby care; and customer concentration. The post-divestment Ontex is cleaner but smaller, more levered relative to EBITDA, and now heavily dependent on European adult care for growth.
Strategy
Strategic evolution
Dec 2021 strategy (Berrozpe): Refocus on partner/retailer brands and healthcare; exit branded emerging markets.
2022–2025 (Calvo Paz): Three-year transformation — divest Emerging Markets; cost transformation (~€70m/yr savings in 2023–2024); invest in capacity in North America and European adult care (2023–2025 investment phase); Belgian footprint optimization; refinancing.
2026 (Nielly): Strategic review (Jan–Jul 2026) leading to a "fundamental transformation" toward a "more focused, resilient, cash-generating and value-driven Ontex" (H1 2026 release).
The four strategic shifts (July 2026)
-
Focus to Value productivity programme: Incremental €40m EBITDA by end-2028 on top of the previously committed €200m savings target, totalling €240m. Levers: production and logistics optimization, simplification, lean manufacturing, streamlined organization (>20% reduction of white-collar positions excluding manufacturing by end-2028). Restructuring cash costs €60–65m over 24 months (of which ~€20m in H2 2026).
-
North America reset: Prioritize profitability over volume, adjust capacity and operational set-up, review the customer portfolio, explore partnership opportunities; return to sustainable cash generation on a right-sized asset base.
-
Accelerate adult care growth in Europe: Adult care becomes the "cornerstone" of growth — capacity, innovation and go-to-market investment to grow ahead of market.
-
Targeted approach in European baby and feminine care: Focus on markets, customers and segments with sustainable returns; simplify product and asset portfolio.
Other initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Emerging Markets exit | 2023–Nov 2025 | Mexico, Algeria, Pakistan, Brazil, Turkey sold | Completed |
| Belgian footprint optimization | Jun 2024–early 2026 | Eeklo closure; Buggenhout CoE (~€40m capex); ~€60m restructuring cost | Finalized in H1 2026 |
| Refinancing | Nov 2024–Jul 2025 | €270m RCF; €400m 2030 notes; €580m 2026 notes repaid | Completed |
| Adult care capacity | Started end-Q3 2025 | Additional adult care capacity in Europe; ramp-up a 2026 priority | Ramping |
| Contract wins | Q3 2025 | New contracts in Europe and North America (lower volumes than expected) | Operational |
| Pricing actions | 2,026 | Pass-through of freight and oil-derivative inflation | Ongoing; impact building in H2 2026 |
| Transformation Management Office | Jul 2026 | Governance for 100+ initiatives | Active |
| Sustainability | Ongoing | EcoVadis Gold (2nd consecutive year, top 3%); CDP Supplier Engagement "A" (May 2026) | Ongoing |
Medium-term guidance
FY2026 (revised 30 Jul 2026): Adj. EBITDA €165–180m (−6% to +3% vs €176m); FCF €(25)–(10)m; leverage below 3.5x at year-end. Previously: adj. EBITDA ~+10%, positive FCF, leverage ≤3.0x.
Medium-term ambition: Management intends to share "financial mid-term ambition and the associated building blocks" in the coming months (H1 2026 release). No quantified medium-term targets are currently in force.
Not yet reflected: The 16 Oct 2026 loss of operational control in Russia (7–8% of adj. EBITDA) post-dates the guidance; an update is expected at Q3 results on 28 Oct 2026.
Products & Services
Ontex's revenue is predominantly retailer brands (products sold under retailers' labels) and healthcare supply; owned brands are concentrated in healthcare adult care. Pricing models are contractual/tender-based and not disclosed product by product. Detailed specifications are generally not publicly disclosed; entries below reflect public descriptions.
Adult care (FY2025 revenue €814.1m)
| Product line / brand | Description | Target customer | Status / latest | Notes |
|---|---|---|---|---|
| iD (Ontex healthcare brand) | Full incontinence range: light pads, medium/heavy all-in-ones, pants, underpads | Healthcare institutions, home care, pharmacies (Europe) | Active | Flagship owned healthcare brand (prior knowledge; not re-verified in this cycle) |
| Serenity | Italian adult incontinence/healthcare brand | Italian healthcare & retail | Active (acquired c. 2013–14) | Status per prior knowledge |
| Lille / Lille Healthcare | Incontinence products for institutional care | Healthcare (France, other EU) | Active | Prior knowledge |
| Euron | German healthcare incontinence brand | German healthcare | Active | Prior knowledge |
| Retailer-brand adult pants and pads | Light/moderate incontinence pads and pull-up pants | European and North American retailers | Active | Growth driven by new capacity started end-Q3 2025 |
| Sensitive range | Incontinence range designed to support better skin health | Healthcare and retail | Launched early 2026 (Ontex news, 2026) | Specifications not disclosed |
| Medium/heavy incontinence (Buggenhout CoE) | Briefs/all-in-ones produced at modernized Buggenhout site | Healthcare | ~€40m investment programme (2024–2026) | Centre of excellence for R&D and production |
Baby care (FY2025 revenue €696.6m)
| Product line / brand | Description | Target customer | Status | Notes |
|---|---|---|---|---|
| Retailer-brand baby diapers (tape) | Full size range, multiple quality tiers (value to premium) | European and North American retailers | Active; volumes −12% in FY2025 | Core historical business |
| Retailer-brand baby pants | Pull-up training/diaper pants | Retailers | Active; double-digit growth in H1 2026 | Key outperformer |
| Contract manufacturing (North America) | Diapers produced for third-party brand owners | Brand owners | Declining (anticipated) | ~1/3 of NA revenue across categories |
| Moltex, Helen Harper | Owned European baby brands | Retail, eco/value segments | Active (per company descriptions) | Listed among brands in Simply Wall St profile |
| Ontex Dreamshields | Owned baby brand | Retail | Listed in third-party profile | Details not disclosed |
| Divested brands | BBTips, Chicolastic, Kiddies, BioBaby (Mexico, sold 2023); Pom Pom, Cremer, Sapeka, Mônica (Brazil, sold 2025); Canbebe (Turkey, sold 2025) | — | Divested | Third-party profiles may still list them |
Feminine care (FY2025 revenue €228.2m)
| Product line / brand | Description | Target customer | Status | Notes |
|---|---|---|---|---|
| Retailer-brand towels, liners, tampons | Full feminine hygiene range | European retailers | Active | Grew slightly ahead of retailer brands in Europe (H1 2026) |
| NAT, Silhouette | Owned feminine care brands | Retail | Listed in third-party profiles | Details not disclosed |
| Contract manufacturing | Feminine products for brand owners | Brand owners | Declining in 2026 | Main driver of −4% volume in H1 2026 |
Services
Ontex describes "our services" on its website (co-development, customer innovation showcases and supply-chain partnership for retailers). These are not separately monetized.
Financial Narrative
Basis: Continuing operations (Core Markets) unless noted. FY2021 figures are not available on a comparable continuing-operations basis in the sources reviewed and are left blank. FY2022 core revenue and adj. EBITDA are derived from the FY2023 release (revenue bridge start-point €1,672.2m; FY2023 core adj. EBITDA €174m stated as +67%).
Income statement: notes and sources
Sources: FY2023 release (Feb 2024), FY2024 release (19 Feb 2025), FY2025 release (12 Feb 2026). FY2022 adj. EBITDA = analyst derivation (€174m ÷ 1.67). Gross profit: not disclosed in the excerpts reviewed (Ontex presents an operating-expense format in its business review). Diluted EPS: not disclosed in excerpts reviewed.
Margins (%)
Revenue CAGR FY2022–FY2025 (continuing): ~1.8% (analyst calculation). FY2024 LFL growth +3.5%; FY2025 LFL −4.9% (headline). Discrepancy: the FY2025 release summary bullet states a "−9% like-for-like decrease" while the headline and business review state −4.9% LFL; reported change (€1,860m → €1,762m) is −5.3%, consistent with −4.9% LFL.
Quarterly trajectory: notes and sources
Sources: quarterly releases. Q1 2025 restated adj. EBITDA €50.5m (Q1 2026 bridge); Q1 2026 adj. EBITDA €38.6m derived from H1 €78.1m less Q2 €39.5m. Discrepancy: the Q1 2026 bridge in the press release shows €38.8m; an earnings-call summary (Investing.com) cites "EUR 30 million" and "9.1% margin" — the €30m figure appears to be a transcription error; the margin (9.1%) is consistent with ~€38.6–38.8m.
Balance sheet and leverage
H1 2026 (30 June 2026): gross debt €619.0m; cash €79.1m; net debt €539.8m (incl. leases ~€146m); NWC €77.3m (4.5% of revenue); leverage 3.22x; liquidity €279m (cash + 75% undrawn of €270m RCF); off-balance-sheet factoring €187m (H1 2026 release).
Sources: FY2023 release (leverage 6.4x at end-2022), FY2024 earnings-call summary (gross debt €834m → €736m; liquidity €322m → €370m), FY2025 release. Total assets, equity, goodwill & intangibles, short/long debt split: not disclosed in sources reviewed (refer to 2025 Annual Report balance sheet). Goodwill impairment of €51m in North America (H1 2026) indicates material residual goodwill.
Debt composition (latest): €400m 5.25% senior unsecured notes due 15 April 2030 (semi-annual coupon); €270m RCF (signed Nov 2024, 5-year, ~25% drawn at June 2026); leases ~€146m; other facilities. The €580m 2026 notes were fully repaid in 2025.
Cash flow
H1 2026: capex €(29.2)m (3.4% of revenue), FCF €6.6m vs €(40.3)m in H1 2025; restructuring cash-out €(11)m; financing cash-out €(20)m. FY2026 FCF guided at €(25)–(10)m. Buyback: 1.5m shares (~€10m cash in 2025 per Q1 2025 presentation). Operating cash flow on a statutory basis: not disclosed in excerpts reviewed.
Ratios
ROE, ROA, ROIC, current ratio, debt/equity, asset turnover and cash conversion cycle: not computed — balance-sheet totals not disclosed in sources reviewed. Qualitatively: ROE was negative in FY2025 (net loss €173.5m) and will be negative in FY2026 (H1 loss €143.0m).
Commentary on trends, inflections and drivers
FY2022 trough: Input-cost inflation (pulp, SAP, energy, freight) crushed margins; core adj. EBITDA margin fell to ~6.2% and Total Group leverage hit 6.4x.
FY2023–FY2024 recovery: A cost transformation programme delivered €72m of savings in 2023 and ~€70m in 2024, reducing the operating cost base ~5% per year; volumes grew ~6% in 2024 (NA double-digit baby growth, adult care, baby pants). Adj. EBITDA rose from €104m to €223m; leverage fell to 2.46x with Mexico proceeds.
FY2025 inflection down: A −5% volume shock (baby −12%), customer destocking, supply-chain disruptions (Q2) and A-brand promotions cut adj. EBITDA 21% to €176m. Non-cash CTA recycling on Brazil and Turkey disposals drove a €190m loss from discontinued operations, resulting in a €173.5m net loss. Leverage rose to 3.29x despite €131m net divestment proceeds.
H1 2026: Revenue stabilized sequentially (Q2 flat YoY), adj. EBITDA margin recovered to 9.2% in Q2, FCF turned positive, but €144m impairments produced a €143m loss. Input-cost inflation from the Middle East crisis (freight from March, oil derivatives from June) forced a guidance cut to €165–180m.
Structural read: Margin volatility is driven mostly by volume (fixed-cost absorption) and the lag of price pass-through. The 2023–2024 margin recovery owed more to cost-out than to commercial strength, and savings have been largely consumed by inflation and volume loss since.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Category (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Adult care revenue | 736.4 | 800.5 | 814.1 |
Baby care revenue | 790.0 | 793.4 | 696.6 |
Feminine care revenue | 241.3 | 236.6 | 228.2 |
Sum of categories | 1,767.7 | 1,830.5 | 1,738.9 |
Group revenue as reported | 1,794.7 | 1,860.0 | 1,762.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Category metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Adult care LFL growth | — | 9.0 | 1.6 |
Baby care LFL growth | — | -0.1 | -11.0 |
Feminine care LFL growth | — | -2.5 | -3.3 |
Adult care share of category revenue | 41.7 | 43.7 | 46.8 |
Baby care share of category revenue | 44.7 | 43.3 | 40.1 |
Feminine care share of category revenue | 13.6 | 12.9 | 13.1 |
Revenue by Segment (Half-Yearly)
| Category H1 (EUR Mn) | H1 2025 | H1 2026 |
|---|---|---|
Adult care revenue | 406.1 | 410.0 |
Baby care revenue | 351.9 | 328.0 |
Feminine care revenue | 114.0 | 106.7 |
Group revenue | 880.3 | 854.8 |
Income Statement and Per-Share Data
| Metric (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (continuing) | — | 1,672.2 | 1,794.7 | 1,860.0 | 1,762.0 |
Adj. EBITDA (continuing) | — | 104.2 | 174.0 | 222.6 | 175.6 |
Total Group adj. EBITDA (incl. discontinued) | — | 135.7 | 223.3 | — | — |
Depreciation and amortization | — | — | — | 74.1 | 77.5 |
Adj. EBIT (analyst calc.) | — | — | — | 148.5 | 98.1 |
EBITDA adjustments (one-offs) | — | — | — | -72.7 | -19.1 |
Operating profit (continuing) | — | — | — | 76.0 | 79.0 |
Net finance cost | — | — | — | -51.4 | -51.1 |
Adj. profit from continuing operations | — | — | — | 75.8 | 30.7 |
Profit from continuing operations | — | — | — | 20.9 | 16.6 |
Loss from discontinued operations | — | — | — | -10.7 | -190.1 |
Profit/(loss) for the period | — | — | — | 10.3 | -173.5 |
Basic EPS (EUR) | — | — | — | 0.13 | -2.16 |
Dividend per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Adj. EBITDA margin | 6.2 | 9.7 | 12.0 | 10.0 |
Adj. EBIT margin | — | — | 8.0 | 5.6 |
Operating margin | — | — | 4.1 | 4.5 |
Net margin (total group) | — | — | 0.6 | -9.8 |
Income Statement and Margin Analysis (%)
| Quarter metric (EUR Mn) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue | 450.6 | 429.7 | 445.4 | 436.0 | 426.3 | 428.5 |
Adj. EBITDA | 50.5 | 35.7 | 50.8 | 39.0 | 38.6 | 39.5 |
Adj. EBITDA margin (%) | 11.2 | 8.3 | 11.4 | 8.9 | 9.1 | 9.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansLiquidity & Coverage Ratios and Financial Ratios (x)
| Balance sheet (EUR Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Gross financial debt | — | 834.0 | 736.3 | 647.4 |
Net financial debt | — | 665.0 | 612.0 | 577.0 |
Net working capital | — | — | 117.5 | 89.0 |
Net debt / adj. EBITDA (x) | 6.4 | 3.25 | 2.46 | 3.29 |
Available liquidity | — | 322.0 | 370.0 | — |
Cash flow (EUR Mn)
| Cash flow (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capex | — | — | — | -112.4 | -81.1 |
Free cash flow (company definition, incl. interest) | — | — | — | 47.9 | -25.1 |
Share buybacks | — | — | — | — | -10.0 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net debt / adj. EBITDA (x) | 6.4 | 3.25 | 2.46 | 3.29 |
Adj. EBITDA / net finance cost (x) | — | — | 4.3 | 3.4 |
Capex / revenue (%) | — | — | 6.0 | 4.6 |
NWC / revenue (%) | — | — | 5.3 | 5.0 |
Region (As Available) Overview
| Region (as available) | Disclosure |
|---|---|
Europe | Majority of revenue; adult care healthcare channel and retailer brands; not quantified in sources reviewed |
North America | Not quantified in sources reviewed; contract manufacturing ≈ one-third of NA revenue (FY2025 presentation); NA retailer-brand baby volumes grew on contract gains through 2025–H1 2026 |
Russia | ~5% of group revenue; 7–8% of adj. EBITDA (Ontex, 16 Oct 2026) — implied ~€87m revenue on LTM basis (analyst calc.) |
Emerging Markets (discontinued, now divested) | Mexico ~€360m sales (2021); Turkey ~€90m sales (2024) |
Region revenue (EUR Mn)
| Region revenue (EUR Mn) | FY2025 |
|---|---|
Russia (approx., ~5% of revenue) | 88 |
Share Price
| Price point (EUR) | Oct 2021 | Oct 2023 | Oct 2025 | Jul 2026 | Oct 2026 |
|---|---|---|---|---|---|
Ontex share price (approx.) | 9.0 | 6.9 | 6.2 | 2.25 | 1.81 |
Return
| Return | Approx. % |
|---|---|
1-year | -70 |
3-year | -74 |
5-year | -80 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | ~€149m | €1.81 × ~82.4m shares |
Enterprise value | ~€689m |
|
EV / LTM adj. EBITDA | ~4.1x | LTM adj. EBITDA €167.5m (FY2025 €175.6m − H1 2025 €86.2m + H1 2026 €78.1m) |
EV / FY2026E adj. EBITDA (guidance midpoint €172.5m) | ~4.0x | Pre-Russia guidance |
EV / LTM sales | ~0.40x | LTM revenue ~€1,736m |
P/B | Not computed | — |
Pro forma leverage ex-Russia (illustrative) | ~3.5x | €540m ÷ (€167.5m − ~€12.5m) — analyst illustration |
Analyst Ratings & Targets
| Date | Action | Target (EUR) | Source |
|---|---|---|---|
21 Jan 2026 | Downgrade to Sell | 4.70 (from 6.30) | Investing.com |
20 Feb 2026 | Hold maintained | 4.90 (from 5.10) | Investing.com |
9 Apr 2026 | Hold maintained | 3.80 (from 4.90) | Investing.com |
21 May 2026 | Hold maintained | 3.30 (from 3.80) | Investing.com |
Jul 2026 | Consensus average | 4.02 (range 3.20–4.70) | Investing.com (pre-H1 results) |
Capital Markets
| Item | Detail |
|---|---|
Fitch | Not rated (no rating identified) |
Senior notes | €400m 5.25% due 15 Apr 2030; NC2 call schedule; 101% change-of-control put; issued 3 Apr 2025 |
Bond trading | ~86.7–87.0% of par; YTM ~9.8–10.0% (DivvyDiary, Oct 2026) |
RCF | €270m, 5-year (signed Nov 2024); ~25% drawn at June 2026 |
Debt Maturity Profile
| Maturity (EUR Mn) | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
Senior notes | 0 | 0 | 0 | 0 | 400 |
RCF commitment (maturity ~2029) | 0 | 0 | 0 | 270 | 0 |
Analyst Conclusions
Management guidance (as of 30 Jul 2026)
-
Adj. EBITDA €165–180m (vs €176m in FY2025), with H2 margin improvement from pricing and productivity.
-
Revenue largely stable.
-
FCF €(25)–(10)m.
-
Leverage below 3.5x at year-end 2026.
-
Mid-term ambition to be communicated in "the coming months."
Consensus growth expectations
Average 12-month price target was ~€4.02 in July 2026 (pre-H1), more than double the current price — implying consensus estimates are lagging the latest developments.
Bull case
-
Self-help is large relative to the equity: €240m of planned savings by 2028 versus ~€168m LTM EBITDA and a ~€149m market cap; even partial net retention could re-rate the equity sharply at ~4x EV/EBITDA.
-
Adult care becomes the growth engine: The category is already ~47% of revenue and still growing despite weak overall markets; new capacity is ramping.
-
Optionality from anchor shareholders: GBL and ENA (~35%) plus a Board Strategy Committee create the conditions for a strategic transaction, NA partnership or take-private at a premium.
Bear case
-
Leverage trap: Removing Russia's EBITDA pushes illustrative leverage toward ~3.5x before restructuring cash costs of €60–65m and negative FCF in 2026; bonds at ~10% YTM signal refinancing risk.
-
Structural baby care decline: Baby revenue fell 12% in FY2025; A-brands keep promoting, and NA contract manufacturing is rolling off.
-
Credibility deficit: Three guidance cuts in 12 months, two CEOs and two CFOs in 2026; savings have repeatedly been absorbed by inflation and volume loss.
Catalysts and monitorables (next 12 months)
| Date / window | Catalyst | What to watch |
|---|---|---|
| 28 Oct 2026 | Q3 2026 results | Russia accounting treatment (deconsolidation/impairment), revised guidance, Q3 pricing pass-through |
| H2 2026 | Mid-term targets | Margin and leverage targets; Focus to Value phasing |
| Ongoing | Russia | Any reversal of interim administration; legal recourse; insurance |
| Ongoing | Rating agencies | Moody's/S&P actions after Russia event |
| 2026–2027 | NA reset | Capacity cuts, customer exits, partnership announcements |
| Feb 2027 | FY2026 results (11 Feb 2027) | Year-end leverage vs <3.5x commitment; FCF |
| Ongoing | Input costs | Oil derivatives, pulp, SAP and freight trends |
| Ongoing | Shareholder register | GBL/ENA moves; new 3%+ holders |
Analyst verdict
Ontex enters the final quarter of 2026 as a deeply discounted, highly levered turnaround whose investment case has shifted from "portfolio clean-up complete, margin recovery under way" (early 2025) to "survive, shrink to profitability, and prove cash generation" (late 2026). The divestment programme achieved its strategic goal — a simpler Europe and North America business with adult care as the largest category — but did so while the remaining core weakened: baby care revenue fell by €97m in a single year, North American investments required €106m of impairments, and adj. EBITDA dropped from €223m to an expected €165–180m. The Russian interim administration compounds the problem by removing operational control over a unit delivering 7–8% of adj. EBITDA at a moment when every euro of EBITDA matters for the leverage ratio.
On the other side of the ledger, the equity now trades at roughly 4x EV/EBITDA with a market value under €150m, against a credible, quantified productivity plan (€240m by 2028), positive H1 2026 free cash flow, improving working capital, no bond maturity until 2030, and a demographically supported adult care franchise. New leadership — an internal CEO who ran Europe and an external CFO with private-label transformation experience — has acted decisively on costs and asset impairments rather than defending past investments.
Our verdict is that Ontex is a high-risk, event-driven special situation rather than a fundamental compounder. The asymmetry is real but conditional on three proofs within 12 months: (1) H2 2026 margin recovery from pricing; (2) a transparent treatment of Russia without covenant or rating stress; and (3) visible Focus to Value savings dropping through to EBITDA. Failure on any one keeps the balance sheet the binding constraint. Given anchor-shareholder concentration, a strategic outcome is a plausible exit route. Investors should size positions accordingly and treat the 28 October Q3 release as the next decisive data point.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background |
|---|---|---|---|
Laurent Nielly | Chief Executive Officer | CEO since 13 Jan 2026; President Europe Division 2021–2025; previously led Ontex Brazil | 25+ years in Europe, US and Latin America; P&G, McKinsey & Company, PepsiCo, Coty; began in finance and strategy |
Stéphane Re | Group CFO | Since 14 Sep 2026 | Group CFO, Partner in Pet Food (CVC/Cinven-owned private label pet food); Group CFO Thai Union Europe/MW Brands 2014–2021; Swiss national |
Annick De Poorter | Chief Innovation & Sustainability Officer | — | — |
Jonas Deroo | Chief HR & Legal Officer | — | — |
Marco Querzoli | Chief Supply Chain Officer | — | — |
New President Europe | President Europe Division | — | — |
New Head of North America | President North America | — | — |
Geoffroy Raskin | Head of Investor Relations (not EMC) | — | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Independence / affiliation | Notes |
|---|---|---|---|
Hans Van Bylen | Chairman | Independent | Chair since at least Dec 2020; former Henkel CEO (prior knowledge) |
Ebrahim Attarzadeh | Non-executive director | — | — |
Inge Boets | Independent director | Independent | — |
Michael Bredael | Non-executive director | Shareholder-affiliated (GBL, prior knowledge) | — |
Lorenzo Grabau | Non-executive director | Co-opted Jan 2026; ratification at May 2026 AGM (all resolutions approved) | Former President & CEO of Kinnevik AB; capital-markets and transformation expertise |
Jesper Hojer | Former director | Resigned (announced Jan 2026) | Former CEO Lidl International |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
11 Dec 2025 | Nielly named CEO-designate (effective May 2026) | Alongside second FY2025 guidance cut |
13 Jan 2026 | Nielly CEO immediately; strategic review; Grabau co-opted | Board signalled "all avenues" for value creation |
30 Jul 2026 | New CFO (Re), new heads of North America and Europe, TMO created | Strategic review conclusions |
14 Sep 2026 | Re starts; Peeters departs | — |
Major Shareholders
| Shareholder | Stake (%) | Source / date |
|---|---|---|
Groupe Bruxelles Lambert (GBL) | ~20.0–20.5 | Octus (Mar 2025); Simply Wall St |
ENA Investment Capital LLP | ~15.1–15.4 | Octus (Mar 2025); Simply Wall St |
Brandes Investment Partners | ~10.3 | Simply Wall St |
The Pamajugo Irrevocable Trust | ~3.4–3.6 | Octus; Simply Wall St |
DNCA Finance / Natixis | ~3.0–3.1 | Octus; Simply Wall St |
Black Creek Investment Management | ~3.0 | Simply Wall St |
Vanguard Group | ~2.9 | Simply Wall St |
Joannes G.H.M. Niessen / Mont Cervin SARL | Below 3% since 23 Mar 2026 (was ~3.1%) | Ontex transparency notice, Mar 2026 |
Goldman Sachs Group | Oscillating around 3% (mostly equivalent financial instruments; e.g., 2.86% on 3 Sep 2026) | Ontex transparency notices, Jun–Sep 2026 |
Dimensional Fund Advisors | ~2.1 | Simply Wall St |
Competitive Landscape
Key Competitors
| Competitor | Categories overlapping Ontex | Model | Relative positioning vs Ontex |
|---|---|---|---|
Procter & Gamble (Pampers, Always, Discreet) | Baby, feminine, adult | Global A-brand | Price leader and promotional aggressor; A-brand promotions cited as cause of retailer-brand share loss in 2025 |
Kimberly-Clark (Huggies, Depend, Kotex) | Baby, adult, feminine | Global A-brand | Major in NA; international personal care being combined with Suzano in a JV (announced 2025; prior knowledge) |
Essity (TENA, Libero, Libresse, Bodyform) | Adult (global leader), baby, feminine | A-brand + healthcare | Direct and strongest competitor in European adult incontinence healthcare |
Drylock Technologies (Belgium, private) | Baby, adult | Private label / innovation | Closest private-label peer in Europe |
First Quality Enterprises (US, private) | Baby, adult, feminine | US private label | Main North American retailer-brand competitor |
Paul Hartmann (MoliCare) | Adult | Healthcare brand | Competes in healthcare incontinence (Germany/Europe) |
Abena (Denmark, private) | Adult | Healthcare brand/distributor | Competes in healthcare tenders |
Fater (P&G/Angelini JV, Italy) | Baby, feminine, adult | Branded | Strong in Italy and Southern Europe |
Attends Healthcare Products | Adult | Healthcare brand | Europe/NA healthcare |
Albaad | Feminine | Private label/contract | Feminine care private label |
Unicharm | Baby, adult, feminine | A-brand (Asia-centric) | Limited European presence |
Peer Comparison FY2025
| Metric | Ontex | Essity | Kimberly-Clark | Procter & Gamble |
|---|---|---|---|---|
Latest FY revenue | €1.76bn (FY2025) | ~SEK 145bn (FY2024, approx.) | ~$20bn (FY2024, approx.) | ~$84bn (FY June 2025, approx.) |
Revenue growth (organic/LFL) | −4.9% (FY2025) | — | — | — |
EBITDA margin | 10.0% adj. (FY2025) | — | — | — |



